Institutional Interest in Amgen Rises as 13F Filings Show Net Accumulation

An analysis of recent 13F filings indicates that institutional investors are marginally increasing their exposure to Amgen Inc (AMGN). Out of a sample of 72 recent filings for the period ending March 31, 2026, 35 funds were found to hold positions in the biotechnology giant. The data suggests a lean toward accumulation, though analysts caution that 13F filings provide an incomplete picture of fund sentiment. Because these reports only disclose long positions and omit short interests or derivatives, the apparent bullishness may not reflect the total net exposure of the funds involved. Between December 31, 2025, and March 31, 2026, the aggregate share count held by the tracked funds grew from 13,674,492 to 14,582,106. This represents a net increase of 907,614 shares, or roughly 6.64%. Within the specific batch of 72 filers, 15 funds increased their stakes, while 13 reduced their holdings and three established new positions. While the increase in institutional ownership is a positive signal, the lagging nature of SEC reporting means these trades occurred weeks prior to the filing. Traders typically view such data as a confirmation of long-term sentiment rather than a catalyst for immediate price volatility.